Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sequence Towards Remission in Depression (STRIDE)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2012 by Helsinki University
Academy of Finland
Information provided by (Responsible Party):
Jesper Ekelund, Helsinki University Identifier:
First received: June 24, 2012
Last updated: June 26, 2012
Last verified: June 2012

In this study the investigators use clinical, biological and imaging markers to develop predictive markers for remission from depression. The investigators compare individuals who have received placebo to individuals who have received 10 mg of escitalopram for one week. In this double-blind, randomized study the investigators a) compare the groups to observe the short-term effects of escitalopram and b) study the predictive value of these observations with respect to remission. Measures include, but are not restricted to, limbic emotional reactivity as assessed by fMRI, emotional processing, emotional memory, autobiographical memory.

Condition Intervention Phase
Drug: escitalopram 10 mg
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Sequence Towards Remission in Depression

Resource links provided by NLM:

Further study details as provided by Helsinki University:

Primary Outcome Measures:
  • Montgomery-Åsberg rating scale [ Time Frame: 7 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 90
Study Start Date: June 2012
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Microgranular cellulose in gelatine capsules.
Drug: Placebo
once daily
Experimental: Escitalopram 10 mg
Escitalopram in gelatine capsule
Drug: escitalopram 10 mg
orally once daily


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Major depressive disorder with current major depressive episode according to a SCID-I/P interview
  • Montgomery-Åsberg depression rating score 15-30
  • Age 18-60

Exclusion Criteria:

  • Borderline, schizoid or schizotypal personality, bipolar or any psychotic disorder
  • Primary diagnosis is anxiety disorder: 300.00, .01, .02, .21, .22, .29, .23, .3, 309.81, 308.3, 293.89
  • Significant current suicidal ideation, or history of a suicide attempt
  • Lifetime substance dependence; Last-year substance abuse; Last month over 24/16 standard doses of alcohol/week; Lifetime use of illicit substances > x5; Any illicit substance use in last month
  • Depressive disorder due to medical condition or chemical substance
  • Antidepressant medication use in last 4 months
  • Severe, unstable somatic illness
  • Use of antipsychotics, mood stabilizers, systemic corticosteroids, β-blockers or daytime benzodiazepines (a small dose of ≤10mg zolpidem once daily is permissible)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01628783

Contact: Jesper Ekelund, MD-PhD +358503317987
Contact: Erkki Isometsa, MD-PhD +35894711

Helsinki University Central Hospital, Psychiatry Centre Recruiting
Helsinki, Finland, 00029
Contact: Jesper Ekelund, MD-PhD    +358503317987   
Contact: Emma Komulainen, MD    +358465260387   
Sponsors and Collaborators
Jesper Ekelund
Academy of Finland
Principal Investigator: Erkki Isometsä, MD-PhD Helsinki University
Principal Investigator: Jesper Ekelund, MD-PhD Helsinki University
  More Information

No publications provided

Responsible Party: Jesper Ekelund, Professor of Psychiatry, Helsinki University Identifier: NCT01628783     History of Changes
Other Study ID Numbers: 2012-002476-14
Study First Received: June 24, 2012
Last Updated: June 26, 2012
Health Authority: Finland: Institutional Review Board

Keywords provided by Helsinki University:
emotional processing
autobiographic memory
moderator of treatment response
mediator of treatment response

Additional relevant MeSH terms:
Depressive Disorder
Behavioral Symptoms
Mental Disorders
Mood Disorders
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antiparkinson Agents
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses processed this record on November 19, 2014